logo
Plus   Neg
Share
Email

Sanofi: Positive Toujeo Study Results In 6 To 17 Years With Type 1 Diabetes

Sanofi (SNYNF,SNY) announced Monday positive results in Phase 3 trial for Toujeo in children and adolescents with type 1 diabetes.

The French drug maker in a statement noted that children and adolescents, aged 6 to 17 years, living with type 1 diabetes achieved comparable reduction in average blood sugar or HbA1c and similar risk of low blood sugar events with Toujeo (insulin glargine 300 Units/mL) compared to insulin glargine 100 Units/mL (Gla-100).

The trial, EDITION JUNIOR, is the first randomized, controlled trial comparing Toujeo vs Gla-100 in this group of patients. The study met its primary endpoint with comparable reductions in average blood sugar over 6 months with both treatments and similar risk of low blood sugar events or hypoglycemia.

The results were presented at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts.

The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on October 17, recommending expanding the current indication for Toujeo in the Europe Union for the treatment of diabetes mellitus in adolescents and children.

The European Commission will make a final decision on the additional indication in the coming months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT